Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop
Alaunos Therapeutics Inc. (NASDAQ:TCRT) shares are down on Monday after the company announced preclinical proof-of-concept data for its lead drug candidate, ALN1003.
Data Results
The latest findings from Alaunos indicate that ALN1003 has shown promising results in diet-induced obesity mouse studies, with treated mice experiencing a mean percent change in body weight loss of up to -12.9%.
Peak reductions in absolute weight loss were observed by Day 13 and remained lower than DIO controls through Day 48.
In the first study, ALN1003 reduced liver weight compared to untreated mice by 43% and by 39% when expressed as a percentage of body weight.
Long-term administration of ALN1003 was associated with lower ALT (alanine aminotransferase; p<0.0001), AST (aspartate aminotransferase), and ALP (alkaline phosphatase), with a trend toward lower total bilirubin (nominal p=0.058) compared to untreated mice.
Additionally, the drug demonstrated favorable changes in metabolic biomarkers, including significant reductions in blood sugar and cholesterol levels.
In these studies, ALN1003 was well tolerated, with no severe adverse effects reported.
The company plans to pursue additional financing to support its ongoing preclinical work and initiatives related to chemistry, manufacturing, and controls.
Development Roadmap
Results from the two studies reinforce the company's strategy to advance additional preclinical and CMC work to optimize formulations while preserving therapeutic drug levels.
Planned next steps include studies to clarify ALN1003's mechanism, including blinded assessment of liver fat and MASLD severity.
The company also intends to refine manufacturing processes through an initial small-scale run followed by larger-scale production.
In parallel, a computational chemistry program is underway to develop and evaluate ALN1003 variants aimed at strengthening intellectual property and identifying next-generation candidates.
These efforts, alongside large animal pharmacokinetic studies, are expected to guide future IND-enabling activities.
TCRT Price Action: Alaunos Therapeutics shares were down 3.13% at $3.09 at the time of publication on Monday.
Photo: Gorodenkoff via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ripple Partner Reaches One Million People With Safe Water
NASDAQ TRADE HALT CONTINUES <UCFIW.O> REASON NOT AVAILABLE AT 03:58 AM
VIPCross-Asset Positioning Amid AI Earnings Scrutiny and the US Election
1. Markets diverged during the week. Between the October 23 and October 30 closes, BTC fell 4.78%, the Nasdaq 100 declined 1.98%, and gold and silver dropped 2.72% and 8.59%, respectively. The DAX, KOSPI, Nikkei 225 and Hang Seng advanced. We focus on differences in growth prospects, valuation sensitivity and risk exposures rather than applying a single directional view across assets. 2. Market reactions to Alphabet's and Intel's earnings brought returns on AI investment into focus. Attention is shifting from the scale of capital expenditure to revenue realization, margins and free cash flow. Lower interest rates can ease discount-rate pressure, but a sustained valuation recovery still requires support from both operating performance and financing conditions. 3. The November 3 US midterm elections and November 6 employment report are key events in the coming week. We monitor how post-election fiscal and legislative agendas may affect interest rates, the dollar and industry operating conditions. Our execution priorities are to manage leverage and concentration, retain margin and exit-liquidity buffers, and avoid treating a single political outcome as an automatic trading signal. 4. Following Binance's disclosure of a security incident, industry attention to endpoint protection, access segregation and coordinated incident response has increased. Key assets to monitor: BTC, the Nasdaq 100, crude oil and gold, alongside upcoming earnings from AAPL, AMD, PLTR, ARM, ANET and QCOM.
HYATT HOTELS CORP <H.N>: JEFFERIES RAISES TARGET PRICE TO $188 FROM $167
Crypto prices
More
